Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Open-Label Study of Safety, Pharmacokinetics, and Activity of Weekly Subcutaneous Pegzilarginase in Subjects <24 Months Old With Arginase 1 Deficiency

NCT06582524 is registered in ClinicalTrials.gov with Immedica Pharma AB as lead sponsor.

NCT NCT06582524
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06582524 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Open-Label Study of Safety, Pharmacokinetics, and Activity of Weekly Subcutaneous Pegzilarginase in Subjects <24 Months Old With Arginase 1 Deficiency
Lead sponsor
Immedica Pharma AB
Phase
Phase 3
Overall status
Completed
Start date
August 30, 2024
Completion date
June 17, 2025
Enrollment
3 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

arginase 1 deficiency